Lamisopt Plus

Per mL Dorzolamide 20 mg, timolol 5 mg

Elevated IOP in patients w/ ocular HTN or open-angle glaucoma.

Adult & childn ≥2 yr 1 drop in affected eye(s) bid.

Hypersensitivity. Bronchial asthma or history of bronchial asthma, or severe COPD. Sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock.

Hepatic & renal impairment. Pregnancy & lactation. Childn. Elderly ≥65 yr or ≥75 yr. Dorzolamide: Discontinue use if signs of serious reactions or hypersensitivity occurs, local ocular adverse effects, primarily conjunctivitis & lid reactions w/ chronic administration. Acute angle-closure glaucoma; bacterial keratitis. Concomitant use w/ oral carbonic anhydrase inhibitor. Not to be administered while wearing contact lenses; reinsert lenses ≥15 min after administration. Timolol: May decrease resting & maximal exercise heart rate. History of chronic bronchitis, emphysema. Gradual w/drawal of treatment in elective surgery. Patients w/ DM. May mask signs & symptoms of acute hypoglycemia, clinical signs of hyperthyroidism (eg, tachycardia). Carefully manage patients suspected of developing thyrotoxicosis to avoid abrupt w/drawal of β-blockers. Cerebrovascular insufficiency, angle-closure glaucoma (use w/ miotic). May potentiate muscle weakness consistent w/ certain myasthenic symptoms (eg, diplopia, ptosis, generalized weakness).

Dorzolamide: Ocular burning, stinging or discomfort immediately following administration, bitter taste following administration, superficial punctate keratitis, signs & symptoms of ocular allergic reaction, blurred vision, tearing, dryness, photophobia, dyspnea, foreign body sensation in eye, palpitation. Timolol: Bradycardia, arrhythmia, hypotension, syncope, heart block, CVA, cerebral ischemia, heart failure, palpitation, cardiac arrest; dizziness, depression, fatigue, lethargy, hallucinations, confusion; ocular irritation including conjunctivitis, blepharitis, keratitis, blepharoptosis, decreased corneal sensitivity, visual disturbances including refractive changes, diplopia, ptosis; bronchospasm (mainly in patients w/ preexisting bronchospastic disease), resp failure, dyspnea; aggravation of myasthenia gravis, alopecia, nausea, localized & generalized rash, dyspnea, foreign body sensation in eye, urticarial, impotence, decreased libido, masked symptoms of hypoglycemia in diabetics, diarrhea.

Dorzolamide: Oral carbonic anhydrase inhibitors. Timolol: Possible additive effect on IOP &/or systemic β-adrenergic blockade w/ systemic β-adrenergic blocking agent. Possible additive effects & production of hypotension &/or marked bradycardia w/ catecholamine-depleting drugs. May have additive effects on prolonging AV conduction w/ Ca-channel blocking agent & cardiac glycoside. Severe bradycardia may occur w/ verapamil. Sinus bradycardia may occur w/ quinidine.

Antiglaucoma Preparations

S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

D